# US 2014/0348865 A1 · Immunogens based on an hiv-1 v1v2 site-of-vulnerability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348865 A1
- Document ID: US20140348865A1
- Status: Published application
- Kind: A1
- Application number: 14/344,589
- Filed: 2012-09-07
- Published: 2014-11-27
- Earliest claimed: 2011-09-12
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Ser.; University of Maryland, Baltimore; University of Washington
- Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Ser.; University of Maryland, Baltimore; University of Washington
- Inventors: Peter Kwong; Jason McLellan; Marie Pancera; Jason Gorman; Mallika Sastry; Kaifan Dai; Tongqing Zhou; John Mascola; Gary Nabel; Masaru Kanekiyo; Yongping Yang; Jiang Zhu; Lai-Xi Wang; William Schief; Chris Carrico; Mohammed Amin
- Web page: https://patentgrep.com/patent/US20140348865A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2740/16011: Human Immunodeficiency Virus, HIV
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

An epitope-scaffold protein, comprising:
(A) a gp120 polypeptide, comprising:
gp120 positions 126-196 according to the HXB2 numbering system and corresponding to the amino acid positions in the amino acid sequence set forth as SEQ ID NO: 1;
a first pair of cross-linked cysteines at positions 126 and 196, and a second pair of crosslinked cysteines at positions 131 and 157;
a first N-linked glycosylation site comprising an asparagine residue at position 160 and a second N-linked glycosylation site comprising an asparagine residue at position 156 or position 173, wherein the first and second glycosylation sites are glycosylated; and
(B) a heterologous scaffold comprising a 1VH8 scaffold; wherein
the 1VH8 scaffold is linked to the gp120 polypeptide, and the epitope scaffold protein specifically binds to monoclonal antibody PG9.

### Claim 55 (depends on 54)

The epitope scaffold protein of claim 54, wherein the 1VH8 scaffold comprises the amino acid sequence set forth as SEQ ID NO: 106.

### Claim 56 (depends on 54)

The epitope scaffold protein of claim 54, wherein the gp120 polypeptide does not comprise any cysteine residues at gp120 positions 127-130, 132-156 and 158-195;

### Claim 57 (depends on 54)

The epitope scaffold protein of claim 54, wherein the gp120 polypeptide comprises at most four amino acid substitutions compared to a wild-type HIV-1 gp120.

### Claim 58 (depends on 57)

The epitope scaffold protein of claim 57, wherein the wild type HIV-1 gp120 comprises an amino acid sequence set forth as any one of SEQ ID NOs: 1-8 or 154-160.

### Claim 59 (depends on 54)

The epitope scaffold protein of claim 54, wherein
the asparagine at position 160 is glycosylated with a Man5GlcNAc2 glycan moiety; and
the asparagine at position 156 or the asparagine at position 173 is glycosylated with a complex glycan.

### Claim 60 (depends on 54)

The epitope scaffold protein of claim 54, wherein monoclonal antibody PG9 specifically binds to the antigen or protein nanoparticle with a KD of 100 μM or less.

### Claim 61 (depends on 54)

A multimer of the epitope scaffold protein of claim 54.

### Claim 62 (depends on 54)

A protein nanoparticle comprising the epitope scaffold protein of claim 54.

### Claim 63 (depends on 62)

The protein nanoparticle of claim 62, wherein the protein nanoparticle is a virus-like particle, a ferritin nanoparticle, an encapsulin nanoparticle or a Sulfur Oxygenase Reductase (SOR) nanoparticle.

### Claim 64 (depends on 54)

An isolated nucleic acid molecule encoding the epitope scaffold protein of claim 54.

### Claim 65 (depends on 64)

The nucleic acid molecule of claim 64 operably linked to a promoter.

### Claim 66 (depends on 65)

A vector comprising the nucleic acid molecule of claim 65.

### Claim 67 (depends on 54)

An immunogenic composition comprising an effective amount of the epitope scaffold protein of claim 54, and a pharmaceutically acceptable carrier.

### Claim 68 (depends on 67)

A method for generating an immune response to HIV-1 gp120 in a subject, comprising administering to the subject an effective amount of the immunogenic composition of claim 67, thereby generating the immune response.

### Claim 69 (depends on 68)

The method of claim 68, wherein the subject has a HIV-1 infection.

### Claim 70 (depends on 67)

A method for treating or preventing an HIV-1 infection in a subject, comprising administering to the subject a therapeutically effective amount of the immunogenic composition of claim 67, thereby treating the subject or preventing HIV-1 infection of the subject.

### Claim 71 (depends on 70)

The method of claim 70, wherein the subject has a HIV-1 infection.

### Claim 72 (depends on 54)

A kit for inducing an immune response to HIV-1 gp120 in a subject, comprising the epitope scaffold protein of claim 54; and instructions for using the kit.
